Peptide-Drug Conjugates: Targeted Therapy, ADCs, and Radiolabeled Peptides

Targeted drug delivery is one of the central ambitions of modern oncology. The problem with most chemotherapy is not that it fails to kill cancer cells — it does — but that it also kills healthy cells, producing the toxic side effects that make cancer treatment so difficult to tolerate. If a toxic drug could be delivered specifically to tumor cells and nowhere else, you could dramatically increase the effective dose while sparing normal tissue.

Peptide-drug conjugates represent one of the most sophisticated approaches to this targeting challenge. By linking a cytotoxic drug, radionuclide, or immunostimulatory payload to a peptide that selectively binds tumor-associated receptors, researchers can create molecular missiles that seek out and destroy cancer cells with a precision that systemic chemotherapy cannot approach.

The clinical success of the broader antibody-drug conjugate (ADC) concept — with multiple approved products and billions in sales — has validated the targeting strategy and created enormous interest in peptide-based alternatives that may offer complementary advantages in cost, manufacturing, and tumor penetration.

The Conjugate Architecture

Every peptide-drug conjugate consists of three components:

The targeting peptide: A peptide sequence with affinity for a receptor, protein, or structural feature preferentially expressed on tumor cells or tumor vasculature. This is the "address label" that directs the conjugate to its destination.

The linker: A chemical bridge between the peptide and the payload. Linker design is critically important — it must be stable in circulation (to prevent premature payload release in healthy tissue) but labile in the tumor microenvironment (to release the payload at the target). Cleavable linkers responsive to tumor-specific proteases, acidic pH, or reducing conditions enable this conditional release.

The payload: The cytotoxic drug, radionuclide, photosensitizer, or immune stimulant that produces the therapeutic effect upon delivery. Highly potent payloads that would be too toxic to administer systemically can be used in conjugates because targeting limits their exposure to healthy tissue.

Tumor-Homing Peptides: The Targeting Vectors

The quality of a peptide-drug conjugate depends entirely on the selectivity and affinity of its targeting peptide. Several categories of tumor-homing peptides have been validated in preclinical and clinical research:

Integrin-Targeting Peptides

Integrins are cell-surface receptors that bind extracellular matrix proteins. The αvβ3 and αvβ5 integrins are strongly overexpressed on tumor vasculature (the blood vessels that feed tumors) and on many solid tumor cells themselves.

RGD peptides (Arg-Gly-Asp) bind αvβ3 with nanomolar affinity. RGD-drug conjugates accumulate preferentially in tumors compared to normal tissue in multiple preclinical cancer models. Several RGD-drug conjugates and RGD-radiolabeled peptides are in clinical trials.

Cilengitide is a cyclic RGD peptide (cyclo-RGDfK) that itself has antitumor effects through integrin blocking. It has served as the targeting moiety in several experimental conjugates.

Receptor-Overexpression Targeting Peptides

Many tumor types overexpress specific peptide hormone receptors far above normal tissue levels. These receptors are ideal targets because:

• Their overexpression creates high-density binding sites on tumor cells
• Their natural ligands (peptides) are already known
• Modified versions of those ligands can be conjugated to payloads

Somatostatin analogues targeting somatostatin receptors (SSTR2 in particular) are the most clinically validated peptide targeting vectors. Neuroendocrine tumors (NETs) massively overexpress SSTR2. This has been exploited in:

• Octreotide scans: Radiolabeled octreotide (SSTR2-targeting somatostatin analogue) for tumor imaging
• DOTATATE/DOTATOC: Chelated somatostatin analogues labeled with gallium-68 for PET imaging or lutetium-177 for therapy
• Lutathera (177Lu-DOTATATE): FDA-approved PRRT (peptide receptor radionuclide therapy) for NETs — one of the clearest commercial successes of the peptide-drug conjugate concept

GnRH analogues: Gonadotropin-releasing hormone receptors are overexpressed in prostate, breast, and ovarian cancers. Conjugates of GnRH analogues with doxorubicin (AEZS-108/Zoptarelin Doxorubicin) reached Phase III, though the program faced efficacy challenges.

Bombesin/GRP analogues: Gastrin-releasing peptide receptors are overexpressed in prostate, breast, and lung cancers. Multiple bombesin-drug and bombesin-radionuclide conjugates are in clinical trials.

Phage-Display Discovered Targeting Peptides

Phage display technology allows researchers to screen billions of random peptide sequences against a target tissue (including living tumor tissue in animals or patients) and identify sequences that accumulate preferentially. This approach has identified several tumor-homing peptides not derived from natural ligands:

RGR peptide: Binds to tumor vasculature in brain tumors specifically, identified by in vivo phage display CREKA: Binds fibrin-fibronectin deposits in tumor stroma iRGD: A modified RGD peptide that penetrates deep into tumor tissue rather than binding only the vasculature surface, enabling better payload delivery to tumor interior

Antibody-Drug Conjugates vs. Peptide-Drug Conjugates

Antibody-drug conjugates (ADCs) are the most commercially successful targeted conjugate platform. Drugs like trastuzumab deruxtecan (Enhertu) and sacituzumab govitecan (Trodelvy) have generated billions in sales and transformed treatment for HER2-positive breast cancer and triple-negative breast cancer respectively.

The antibody provides exquisite specificity through its large, evolutionarily optimized binding domain. But antibodies also have limitations:

• Size: At ~150 kDa, antibodies penetrate solid tumors poorly. Tumor penetration depth is physically limited for molecules this large.
• Immunogenicity: Antibodies can cause immune reactions, especially with repeat dosing
• Manufacturing cost: Monoclonal antibody production is expensive (bioreactors, Protein A purification, extensive QC)
• Half-life: Long half-life is sometimes advantageous but can prolong toxicity if off-target binding occurs

Peptide-drug conjugates offer complementary advantages:

• Size: Small peptides (10–30 amino acids) penetrate deeply into solid tumor tissue
• Manufacturing: Solid-phase peptide synthesis is scalable and cheaper than antibody production
• Rapid clearance: If an off-target binding event occurs, the small peptide conjugate clears quickly, limiting unintended toxicity
• Customization: Peptide sequences can be precisely engineered and modified more readily than antibodies

The tradeoff is lower binding affinity in most cases — antibodies achieve picomolar affinities that most peptides cannot match — and shorter circulation time, which reduces tumor accumulation relative to long-circulating ADCs.

Radiolabeled Peptides: Theranostics

One of the most exciting clinical applications of peptide-drug conjugates is theranostics — the combined use of the same peptide conjugate for both tumor imaging (diagnostics) and tumor treatment (therapy), simply by switching the attached radionuclide.

Gallium-68 DOTATATE produces PET/CT images that light up somatostatin receptor-positive NETs with extraordinary clarity. The same DOTATATE peptide conjugated to lutetium-177 (a beta-emitting radionuclide) becomes Lutathera — a therapy that delivers targeted radiation to SSTR2-positive tumors. Inject the same molecule, switch the metal, change the function from imaging to therapy.

This theranostic concept is now being applied beyond somatostatin receptors:

PSMA-targeting peptides: Prostate-specific membrane antigen (PSMA) is massively overexpressed in prostate cancer. 68Ga-PSMA-11 for imaging and 177Lu-PSMA-617 (Pluvicto, FDA approved 2022) for therapy represent the second major clinical success of the theranostic peptide paradigm.

Fibroblast activation protein (FAP) peptides: FAP is expressed on cancer-associated fibroblasts in many solid tumors. 68Ga-FAPI ligands produce superior imaging in several tumor types compared to FDG-PET, and 177Lu-FAPI conjugates are in clinical trials.

The peptide clinical trials 2026 landscape includes numerous theranostic peptide programs in Phase I/II, and the PSMA success has attracted substantial investment to this area.

Photodynamic Therapy Conjugates

A less common but mechanistically elegant approach is conjugating tumor-homing peptides to photosensitizers — molecules that generate reactive oxygen species when activated by specific wavelengths of light. After the conjugate accumulates in the tumor, a light source (typically delivered via endoscope or interstitial fiber optic) activates the photosensitizer, killing tumor cells through oxidative damage.

This approach is being explored for accessible tumors: bladder cancer (endoscopic light delivery), esophageal cancer, and head and neck tumors. Peptide-targeted photodynamic therapy may offer superior selectivity compared to non-targeted photosensitizers.

Formulation and Delivery Considerations

Peptide-drug conjugates face unique formulation challenges. The conjugation chemistry must be stable under physiological conditions but allow payload release at the target site. Quality control must verify that the peptide, linker, and payload are intact and properly conjugated in each manufacturing batch.

Nanoparticle delivery systems can encapsulate peptide-drug conjugates to protect them during circulation and provide additional targeting properties, creating multi-functional delivery systems with layered targeting — the nanoparticle provides EPR-based tumor accumulation, and the peptide targeting provides cell-specific binding.

Frequently Asked Questions

Q: What is the difference between a peptide-drug conjugate and an antibody-drug conjugate? Both use a targeting molecule linked to a cytotoxic payload, but the targeting molecule differs. ADCs use monoclonal antibodies (large, ~150 kDa, very high affinity). Peptide-drug conjugates use short peptides (small, 1–5 kDa, moderate affinity). Peptides penetrate tumors better due to smaller size, are cheaper to manufacture, and clear faster. Antibodies have higher specificity and longer circulation.

Q: How does Lutathera work and is it a peptide-drug conjugate? Yes. Lutathera (177Lu-DOTATATE) is a radiolabeled peptide — DOTATATE is a synthetic somatostatin analogue that targets SSTR2, conjugated through a DOTA chelator to lutetium-177 (a beta-emitting radionuclide). After injection, it accumulates in SSTR2-positive neuroendocrine tumor cells, where the lutetium-177 delivers targeted beta radiation. It is FDA-approved for gastroenteropancreatic NETs.

Q: What cancers are most likely to be treated with peptide-drug conjugates? Neuroendocrine tumors (through somatostatin receptor targeting), prostate cancer (PSMA), and other receptor-overexpressing solid tumors are the current leaders. The strategy is theoretically applicable to any cancer with a receptor or surface protein that is overexpressed relative to normal tissue.

Q: Are peptide-drug conjugates available for off-label or research use? Approved peptide-drug conjugates like Lutathera and Pluvicto are available for their approved indications and at sites with appropriate nuclear medicine infrastructure. Experimental peptide-drug conjugates are only available through clinical trials.

Q: Can peptide-drug conjugates be combined with checkpoint inhibitors? Yes, and this is an active area of research. The hypothesis is that targeted tumor cell killing by peptide-drug conjugates releases tumor antigens, which can then be recognized by the immune system potentiated by checkpoint blockade. Several Phase I/II trials are evaluating such combinations.